Cardiovascular Diseases Clinical Trial
Official title:
Cardiometabolic Benefits of Potatoes Mediated Along the Gut-Vessel Axis in Adults With Metabolic Syndrome
NCT number | NCT03624569 |
Other study ID # | 2018H0265 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | August 15, 2018 |
Est. completion date | July 2020 |
This study is focused on assessing potential health benefits of daily consumption of potatoes, specifically its resistant starch content (i.e. nondigestible carbohydrate), on blood vessel and gut health function in adults with metabolic syndrome. It is expected that the daily consumption of potatoes for two weeks, within a diet that follows the Dietary Guidelines for Americans, will improve blood vessel function in association with decreasing gut permeability ("leaky gut") that results in the absorption of bacterial toxins that reside in the intestine. Outcomes will therefore support dietary recommendations for potatoes to support vascular and gastrointestinal health.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | July 2020 |
Est. primary completion date | July 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Fasting glucose 100-125 mg/dL - Waist circumference >102 cm (men), >88 cm (women) - Fasting triglyceride >150 mg/dL - Fasting HDL cholesterol <40 mg/dL (men), <50 mg/dL (women) - Non-smoker - Non-dietary supplement user (>1-mo) - Free of gastrointestinal disorders, cardiovascular disease, cancer - No recent use of antibiotics or any medications affecting glycemia, lipidemia, or blood pressure Exclusion Criteria: - Use of anti-inflammatory agents or probiotics - Vegetarian, gluten-intolerant, carbohydrate-restricted diet - Alcohol intake >2 drinks/d - >7 hours/week of aerobic activity - Women who are pregnant or lactating or have initiated or changed birth control in the past 3-months - Taking medications that affect blood sugar, blood pressure, blood vessel health, or inflammation - High blood pressure or any vascular diseases - HIV, hepatitis, or blood disorders such as hemophilia - Gastrointestinal disorders - Cancer (current or past history) - Anemia |
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University | Alliance for Potato Research and Education |
United States,
Camire ME, Kubow S, Donnelly DJ. Potatoes and human health. Crit Rev Food Sci Nutr. 2009 Nov;49(10):823-40. doi: 10.1080/10408390903041996. Review. — View Citation
DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001 Feb 12;161(3):397-405. — View Citation
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015 Jan 27;131(4):e29-322. doi: 10.1161/CIR.0000000000000152. Epub 2014 Dec 17. Erratum in: Circulation. 2015 Jun 16;131(24):e535. Circulation. 2016 Feb 23;133(8):e417. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Endotoxin | Fasting serum endotoxin concentration | Day 14 | |
Primary | Vascular endothelial function | Area under curve (change from baseline) for flow-mediated dilation of brachial artery | Day 14 Postprandial (0, 30, 60, 90, 120 minutes) | |
Secondary | Fasting Glucose Day 0 | Fasting plasma glucose | Fasting glucose on Day 0 | |
Secondary | Fasting Glucose Day 14 | Fasting plasma glucose | Fasting glucose on Day 14 | |
Secondary | Fasting Insulin Day 0 | Fasting plasma insulin | Fasting insulin on Day 0 | |
Secondary | Fasting Insulin Day 14 | Fasting plasma insulin | Fasting insulin on Day 14 | |
Secondary | Postprandial Insulin | Plasma insulin concentration area under curve change from baseline | Day 14 postprandial (0, 30, 60, 90, 120 minutes) | |
Secondary | Postprandial Glucose | Postprandial plasma glucose concentration area under curve change from baseline | Day 14 postprandial (0, 30, 60, 90, 120 minutes) | |
Secondary | Fasting Endotoxin | Fasting serum endotoxin concentration | Day 0 | |
Secondary | Postprandial Endotoxin | Postprandial serum endotoxin concentration area under curve change from baseline | Day 14 postprandial (0, 30, 60, 90, 120 minutes) | |
Secondary | Lactulose/mannitol ratio | Urinary concentration of the non-digestible sugars lactulose/mannitol | Day 14, 0-5 hours post-consumption of sugar probes | |
Secondary | Sucralose/erythritol ratio | Urinary concentration of the non-digestible sugars sucralose/erythritol | Day 14, 6-24 hours post-consumption of sugar probes | |
Secondary | Fecal butyrate | Fecal concentration of butyrate | Day 14 | |
Secondary | Fecal acetate | Fecal concentration of acetate | Day 14 | |
Secondary | Fecal propionate | Fecal concentration of propionate | Day 14 | |
Secondary | Postprandial Cholecystokinin | Plasma CCK area under curve change from baseline | Day 14 postprandial (0, 30, 60, 90, 120 minutes) | |
Secondary | Postprandial glucagon-like peptide-1 | Plasma GLP-1 area under curve change from baseline | Day 14 postprandial (0, 30, 60, 90, 120 minutes) | |
Secondary | Postprandial Gastric inhibitory peptide | Plasma GIP area under curve change from baseline | Day 14 postprandial (0, 30, 60, 90, 120 minutes) | |
Secondary | Fasting cholecystokinin | Fasting plasma concentration of CCK | Day 14 | |
Secondary | Fasting GLP-1 | Fasting plasma concentration of GLP-1 | Day 14 | |
Secondary | Fasting Gastric inhibitory peptide | Fasting plasma concentration of GIP | Day 14 | |
Secondary | Postprandial NOx | Plasma total nitrite/nitrate area under curve change from baseline | Day 14 postprandial (0, 30, 60, 90, 120 minutes) | |
Secondary | Fasting NOx | Fasting plasma concentration of nitrite/nitrate | Day 14 | |
Secondary | Postprandial Malondialdehyde (MDA) | Plasma MDA concentration, biomarker of oxidative stress area under curve change from baseline | Day 14 postprandial (0, 30, 60, 90, 120 minutes) | |
Secondary | Fasting Malondialdehyde (MDA) | Fasting plasma MDA concentration, biomarker of oxidative stress | Day 14 | |
Secondary | Fasting Vascular Endothelial Function | Fasting flow-mediated dilation of the brachial artery | Day 14 | |
Secondary | Vitamin C | Fasting vitamin C concentration, biomarker of oxidative stress | Day 14 | |
Secondary | cIMT | Carotid intima-media thickness | Day 14 | |
Secondary | Day 0 weight | Weight in kilograms | Day 0 | |
Secondary | Day 7 weight | Weight in kilograms | Day 7 | |
Secondary | Day 14 weight | Weight in kilograms | Day 14 | |
Secondary | Day 0 height | Height in centimeters | Day 0 | |
Secondary | Day 7 height | Height in centimeters | Day 7 | |
Secondary | Day 14 height | Height in centimeters | Day 14 | |
Secondary | Day 0 waist circumference | Waist circumference in centimeters | Day 0 | |
Secondary | Day 7 waist circumference | Waist circumference in centimeters | Day 7 | |
Secondary | Day 14 waist circumference | Waist circumference in centimeters | Day 14 | |
Secondary | Day 0 diastolic blood pressure | Diastolic blood pressure | Day 0 | |
Secondary | Day 7 diastolic blood pressure | Diastolic blood pressure | Day 7 | |
Secondary | Day 14 diastolic blood pressure | Diastolic blood pressure | Day 14 | |
Secondary | Day 0 systolic blood pressure | Systolic blood pressure | Day 0 | |
Secondary | Day 7 systolic blood pressure | Systolic blood pressure | Day 7 | |
Secondary | Day 14 systolic blood pressure | Systolic blood pressure | Day 14 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|